Introduction
Methods
Study design and study population
Clinical characteristics
Comorbidity
Pharmacotherapy
Statistical analysis
Results
Group | ASPR of statin use in 1999 | Summary | Trend 1 | Trend2 | Trend3 | |||
---|---|---|---|---|---|---|---|---|
AAPC | Years | APC | Years | APC | Years | APC | ||
Total | 8.4% | 12.5 [10.9; 14.1]* | 1999–2005 | 25.4 [21.8; 29.0]* | 2005–2013 | 3.7 [1.7; 5.6]* | ||
Women | 6.5% | 12.6 [10.9; 14.3]* | 1999–2005 | 25.0 [21.3; 28.8]* | 2005–2013 | 4.1 [2.1; 6.2]* | ||
50–59 | 7.6% | 8.3 [5.7; 10.8]* | 1999–2005 | 21.0 [15.5; 26.9]* | 2005–2013 | −0.4 [− 3.4; 2.6] | ||
60–69 | 13.6% | 7.3 [5.1; 9.6]* | 1999–2006 | 15.2 [11.4; 19.2]* | 2006–2013 | −0.1 [− 3.4; 3.3] | ||
70–79 | 6.6% | 14.0 [12.1; 16.0]* | 1999–2004 | 31.0 [27.7; 34.4]* | 2004–2008 | 11.2 [5.0; 17.8]* | 2008–2013 | 1.3 [− 1.3; 3.9] |
80+ | 1.2% | 23.2 [17.3; 29.4]* | 1999–2005 | 40.0 [26.8; 54.5]* | 2005–2013 | 11.9 [5.0; 19.3]* | ||
Men | 10.0% | 12.3 [10.7; 13.9]* | 1999–2005 | 25.4 [21.8; 29.0]* | 2005–2013 | 3.4 [1.5; 5.3]* | ||
50–59 | 18.3% | 6.5 [4.7; 8.4]* | 1999–2005 | 17.2 [13.2; 21.4]* | 2005–2013 | −0.8 [− 3.0; 1.5] | ||
60–69 | 12.7% | 10.7 [9.0; 12.4]* | 1999–2005 | 24.9 [21.2; 28.8]* | 2005–2013 | 1.0 [− 0.9; 3.1] | ||
70–79 | 7.6% | 15.5 [13.7; 17.4]* | 1999–2005 | 29.2 [25.1; 33.3]* | 2005–2013 | 6.2 [4.1; 8.4]* | ||
80+ | 0.8% | 28.0 [22.8; 33.3]* | 1999–2005 | 59.1 [46.5; 72.9]* | 2005–2013 | 8.7 [3.0; 14.6]* |
Group | ASIR of CV/heart disease in 1999 | Summary | Trend 1 | Trend2 | ||
---|---|---|---|---|---|---|
AAPC | Years | APC | Years | APC | ||
Total | 51.7‰ | −3.9 [− 7.4; −0.4]* | 1999–2001 | −13.7 [− 34.4; 13.5] | 2001–2013 | −2.2 [− 3.8; − 0.6]* |
Women | 50.3‰ | −2.8 [− 4.5; − 1.1]* | 1999–2013 | −2.8 [− 4.5; − 1.1]* | ||
50–59 | 34.5‰ | −1.2 [− 6.5; 4.4] | 1999–2013a | −1.2 [− 6.5; 4.4] | ||
60–69 | 33.2‰ | − 0.7 [− 3.8; 2.5] | 1999–2013 | − 0.7 [− 3.8; 2.5] | ||
70–79 | 50.5‰ | −3.3 [− 6.7; 0.1] | 1999–2013 | −3.3 [− 6.7; 0.1] | ||
80+ | 66.6‰ | −3.7 [−5.4; − 2.1]* | 1999–2013 | −3.7 [− 5.4; − 2.1]* | ||
Men | 52.8‰ | −3.3 [− 5.1; − 1.5]* | 1999–2013 | −3.3 [− 5.1; − 1.5]* | ||
50–59 | 33.5‰ | −1.1 [− 4.9; 2.9] | 1999–2013 | − 1.1 [− 4.9; 2.9] | ||
60–69 | 51.4‰ | − 3.3 [− 5.4; − 1.1]* | 1999–2013 | − 3.3 [− 5.4; − 1.1]* | ||
70–79 | 58.0‰ | −3.7 [− 6.3; − 1.1]* | 1999–2013 | −3.7 [− 6.3; − 1.1]* | ||
80+ | 64.1‰ | −3.2 [− 5.5; − 0.8]* | 1999–2013 | −3.2 [− 5.5; − 0.8]* |
Group | ASIR of CV/heart disease in 1999 | Summary | Trend 1 | Trend2 | ||
---|---|---|---|---|---|---|
AAPC | Years | APC | Years | APC | ||
Total | 51.7‰ | −3.9 [− 7.4; − 0.4]* | 1999–2001 | − 13.7 [− 34.4; 13.5] | 2001–2013 | −2.2 [− 3.8; − 0.6]* |
Statin users | 69.5‰ | −3.4 [− 6.7; 0.1] | 1999–2001 | − 34.5 [− 62.6; 14.7] | 2001–2013 | −0.4 [− 3.7; 2.9] |
50–59a | 28.3‰a | 2.6 [−4.3; 9.9] | 2001–2013 | 2.6 [− 4.3; 9.9] | ||
60–79 | 37.3‰ | −0.5 [− 2.8; 1.9] | 1999–2013 | −0.5 [− 2.8; 1.9] | ||
80 + b | 55.9‰b | −7.2 [− 29.0; 21.3] | 2004–2013 | −7.2 [− 29.0; 21.3] | ||
Statin non-users | 52.6‰ | −3.2 [−4.4; − 2.0]* | 1999–2001 | − 14.1 [− 33.8; 11.6] | 2001–2013 | − 2.3 [− 3.8; − 0.8]* |
50–59 | 37.3‰ | −1.8 [−6.7; 3.3] | 1999–2013 | − 1.8 [− 6.7; 3.3] | ||
60–79 | 51.7‰ | −3.2 [− 4.6; − 1.7]* | 1999–2013 | −3.2 [− 4.6; − 1.7]* | ||
80+ | 64.2‰ | −3.4 [− 5.0; − 1.8]* | 1999–2013 | −3.4 [− 5.0; − 1.8]* |
Variables | 1999 | 2013 | Age group in 2013 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Total (n = 4007) | Total (n = 6295) | 50–59 years (n = 1077) | 60–79 years (n = 3211) | 80+ years (n = 2077) | |||||||
n (%) or Median [P25; P75] | n (%) or Median [P25; P75] | n (%) or Median [P25; P75] | Statin use cat.a % | Statin use ref. cat.b % | n (%) or Median [P25; P75] | Statin use cat.a % | Statin use ref. cat.b % | n (%) or Median [P25; P75] | Statin use cat.a % | Statin use ref. cat.b % | |
Statin use, n (%) | 295 (7.4) | 2477 (39.3) | 330 (32.8) | 1614 (50.3) | 533 (25.7) | ||||||
Baseline characteristics | |||||||||||
Age (years), median [IQR] | 73 [66; 79] | 74 [64; 82] | 55 [52; 57] | 70 [65; 75] | 85 [82; 89] | ||||||
Women, n (%) | 1839 (45.9) | 2871 (45.6) | 448 (44.5) | 24.1*** | 39.7 | 1280 (39.9) | 41.6*** | 56.0 | 1143 (55) | 20.4*** | 32.1 |
LDL measurement, n (%) | 1559 (38.9) | 2405 (38.2) | 421 (42.0) | 23.3*** | 39.6 | 1040 (32.4) | 38.8*** | 55.8 | 944 (45.5) | 14.6*** | 34.9 |
Type of CVD history | |||||||||||
MI, n (%) | 848 (21.2) | 1507 (23.9) | 331 (32.9) | 36.3* | 31.1 | 786 (24.5) | 59.0*** | 47.4 | 390 (18.8) | 31.0** | 24.4 |
Stroke, n (%) | 831 (20.7) | 1496 (23.8) | 248 (24.6) | 29.8 | 33.7 | 672 (20.9) | 46.3** | 51.3 | 576 (27.7) | 20.5*** | 27.6 |
TIA, n (%) | 631 (15.7) | 963 (15.3) | 67 (6.7) | 41.8 | 32.1 | 414 (12.9) | 49.3 | 50.4 | 482 (23.2) | 21.8** | 26.8 |
IHD without angina, n (%) | 754 (18.8) | 1147 (18.2) | 144 (14.3) | 42.4** | 31.2 | 648 (20.2) | 61.3*** | 47.5 | 355 (17.1) | 33.2*** | 24.1 |
IHD with angina, n (%) | 1582 (39.5) | 1809 (28.7) | 173 (17.2) | 46.8*** | 29.9 | 938 (29.2) | 54.1** | 48.7 | 698 (33.6) | 27.5 | 24.7 |
PAD, n (%) | 1011 (25.2) | 1669 (26.5) | 242 (24.0) | 27.3** | 34.5 | 873 (27.2) | 45.9** | 51.9 | 554 (26.7) | 27.4 | 25.0 |
Comorbidities | |||||||||||
Atrial fibrillation, n (%) | 430 (10.7) | 870 (13.8) | 24 (2.4) | 45.8 | 32.5 | 359 (11.2) | 53.8 | 49.8 | 487 (23.4) | 21.1** | 27.0 |
Hypercholesterolemia, n (%) | 1040 (26.0) | 2075 (33.0) | 292 (29.0) | 50.7*** | 25.5 | 1134 (35.3) | 60.6*** | 44.6 | 649 (31.2) | 34.2*** | 21.8 |
Hypertension, n (%) | 1396 (34.8) | 2772 (44.0) | 344 (34.2) | 36.6* | 30.8 | 1422 (44.3) | 51.7 | 49.1 | 1006 (48.4) | 24.8 | 26.5 |
Mental disorder, n (%) | 625 (15.6) | 1310 (20.8) | 289 (28.7) | 32.5 | 32.9 | 627 (19.5) | 45.1** | 51.5 | 394 (19.0) | 17.5*** | 27.6 |
Co-medications | |||||||||||
Aspirin and antihypertensive agents | |||||||||||
Aspirin + RAS and Non-RAS | 75 (1.9) | 707 (11.2) | 88 (8.7) | Ref cat | 458 (14.3) | Ref cat | 161 (7.8) | Ref cat | |||
Aspirin + RAS or Non-RAS, n (%) | 295 (7.4) | 1464 (23.3) | 171 (17.0) | 73.5 | 80.7 | 959 (29.9) | 73.7** | 81.0 | 334 (16.1) | 63.0** | 70.8 |
Aspirin alone, n (%) | 68 (1.7) | 226 (3.6) | 45 (4.5) | 68.9 | 80.7 | 147 (4.6) | 58.5*** | 81.0 | 34 (1.6) | 44.1*** | 70.8 |
RAS or Non-RAS and no aspirin, n (%) | 702 (17.5) | 1808 (28.7) | 256 (25.4) | 38.7*** | 80.7 | 1014 (31.6) | 60.4*** | 81.0 | 538 (25.9) | 44.8*** | 70.8 |
None of these 3 categories, n (%) | 2942 (73.4) | 2797 (44.4) | 535 (53.1) | 12.7*** | 80.7 | 1091 (34.0) | 16.1*** | 81.0 | 1171 (56.4) | 4.6*** | 70.8 |
Other lipid-lowering medication | 73 (4.3) | 237 (3.8) | 37 (3.7) | 48.6** | 32.2 | 164 (5.1) | 43.3* | 50.6 | 36 (1.7) | 30.6 | 25.6 |
Charlson comorbidity index | |||||||||||
mCCI indexc, median [IQR] | 5 [3; 6] | 5 [4; 7] | 3 [2; 4] | 5 [4; 6] | 7 [6; 8] | ||||||
MI/ IHD w/o angina, n (%) | 1395 (34.8) | 2364 (37.6) | 442 (43.9) | 36.4** | 29.9 | 1269 (39.5) | 59.3*** | 44.3 | 653 (31.4) | 32.3*** | 22.6 |
Heart failure, n (%) | 364 (9.1) | 500 (7.9) | 20 (2.0) | 55.0** | 32.3 | 156 (4.9) | 59.6** | 49.8 | 324 (15.6) | 19.1** | 26.9 |
PAD, n (%) | 1011 (25.2) | 1669 (26.5) | 242 (24.0) | 27.3** | 34.5 | 873 (27.2) | 45.9** | 51.9 | 554 (26.7) | 27.4 | 25.0 |
TIA/stroke, n (%) | 1333 (33.3) | 2283 (36.3) | 305 (30.3) | 31.8 | 33.2 | 1014 (31.6) | 46.6** | 51.9 | 964 (46.4) | 21.1*** | 29.6 |
Dementia, n (%) | 94 (2.3) | 301 (4.8) | 17 (1.7) | 23.5 | 32.9 | 87 (2.7) | 40.2* | 50.5 | 197 (9.5) | 14.7*** | 26.8 |
COPD/asthma, n (%) | 579 (14.4) | 1580 (25.1) | 276 (27.4) | 31.9 | 33.1 | 862 (26.8) | 48.4 | 51.0 | 442 (21.3) | 24.7 | 25.9 |
GI ulcer, n (%) | 471 (11.8) | 647 (10.3) | 65 (6.5) | 30.8 | 32.9 | 331 (10.3) | 49.5 | 50.3 | 251 (12.1) | 21.9 | 26.2 |
Liver disease, n (%) | 110 (2.7) | 361 (5.7) | 52 (5.2) | 40.4 | 32.4 | 200 (6.2) | 48.0 | 50.4 | 109 (5.2) | 20.2 | 26.0 |
Diabetes mellitus, n (%) | 644 (16.1) | 1587 (25.2) | 235 (23.3) | 38.7** | 31.0 | 855 (26.6) | 58.9*** | 47.1 | 497 (23.9) | 27.4 | 25.1 |
Paralysis, n (%) | 122 (3.0) | 141 (2.2) | 18 (1.8) | 55.6** | 32.4 | 65 (2.0) | 43.1 | 50.4 | 58 (2.8) | 15.5* | 26.0 |
Cancer, n (%) | 382 (9.5) | 1207 (19.2) | 191 (19.0) | 20.9*** | 35.5 | 631 (19.7) | 43.3*** | 52.0 | 385 (18.5) | 23.4 | 26.2 |
Leukaemia, n (%) | 9 (0.2) | 40 (0.6) | 10 (1.0) | 20.0 | 32.9 | 15 (0.5) | 46.7 | 50.3 | 15 (0.7) | 33.3 | 25.6 |
Hodgkin’s lymphoma, n (%) | 12 (0.3) | 44 (0.7) | 6 (0.6) | 16.7 | 32.9 | 27 (0.8) | 40.7 | 50.3 | 11 (0.5) | 36.4 | 25.6 |
HIV-infection/ AIDS, n (%) | NA | NA | NA | ||||||||
Renal insufficiencyd, n (%) | |||||||||||
Yes vs no | 468 (11.7) | 665 (10.6) | 14 (1.4) | 50.0 | 37.7 | 192 (6.0) | 49.5 | 54.6 | 459 (22.1) | 25.3** | 31.9 |
Not measured vs measured | 755 (18.8) | 970 (15.4) | 214 (21.3) | 13.6*** | 38.0 | 372 (11.6) | 19.6*** | 54.3 | 384 (18.5) | 6.0*** | 30.1 |
Variables | Multivariable analysis (50–59 years) | Multivariable analysis (60–79 years) | Multivariable analysis (80+ years) | |||
---|---|---|---|---|---|---|
OR [95%CI] | p-value | OR [95% CI] | p-value | OR [95% CI] | p-value | |
Baseline characteristics | ||||||
Age, per year increase | 1.25 [1.02; 1.52] | 0.030 | 0.87 [0.84; 0.90] | < 0.001 | ||
Women | 0.59 [0.42; 0.84] | 0.003 | 0.64 [0.54; 0.77] | < 0.001 | 0.68 [0.51; 0.89] | 0.005 |
LDL measurement | 0.64 [0.49; 0.83] | 0.001 | 0.50 [0.37; 0.68] | < 0.001 | ||
Type of CVD history | ||||||
MI | 1.42 [1.15; 1.75] | 0.001 | ||||
IHD without angina | 1.40 [1.12; 1.75] | 0.003 | 1.48 [1.06; 2.09] | 0.022 | ||
IHD with angina | 1.60 [1.04; 2.45] | 0.030 | 1.36 [1.03; 1.80] | 0.033 | ||
Comorbidities | ||||||
Atrial fibrillation | 0.66 [0.48; 0.92] | 0.013 | ||||
Hypercholesterolemia | 3.59 [2.45; 5.30] | < 0.001 | 2.40 [1.98; 2.92] | < 0.001 | 2.93 [2.18; 3.97] | < 0.001 |
Hypertension | 0.65 [0.44; 0.96] | 0.030 | 0.58 [0.48; 0.70] | < 0.001 | 0.65 [2.18; 3.97] | 0.002 |
Mental disorder | 0.63 [0.43; 0.91] | 0.015 | ||||
Co-medications | ||||||
Aspirin and antihypertensive agents | ||||||
Reference: Aspirin + RAS and | 1.00 | 1.00 | 1.00 | |||
Non-RAS | ||||||
Aspirin + RAS or Non-RAS | 0.63 [0.28; 1.35] | 0.236 | 0.61 [0.44; 0.85] | 0.004 | 0.67 [0.40; 1.12] | 0.126 |
Aspirin alone | 0.48 [0.19; 1.19] | 0.110 | 0.23 [0.15; 0.36] | < 0.001 | 0.30 [0.13; 0.71] | 0.006 |
RAS or Non-RAS | 0.15 [0.08; 0.28] | < 0.001 | 0.36 [0.27; 0.47] | < 0.001 | 0.37 [0.24; 0.57] | < 0.001 |
None of these 3 categories | 0.03 [0.01; 0.06] | < 0.001 | 0.04 [0.03; 0.05] | < 0.001 | 0.02 [0.01; 0.03] | < 0.001 |
Other lipid lowering medication | 0.39 [0.17; 0.88] | 0.024 | 0.24 [0.17; 0.35] | < 0.001 | 0.19 [0.08; 0.42] | < 0.001 |
Charlson comorbidity index | ||||||
mCCI indexa | 0.89 [0.83; 0.95] | < 0.001 | ||||
Liver disease | 0.54 [0.28; 1.00] | 0.054 | ||||
Diabetes, mellitus | 1.52 [1.22; 1.88] | < 0.001 | ||||
Paralysis | 5.12 [1.51; 17.60] | 0.009 | ||||
Cancer | 0.63 [0.39; 1.01] | 0.059 | ||||
Renal insufficiency | ||||||
Yes | 1.88 [0.53; 6.60] | 0.318 | 0.98 [0.65; 1.46] | 0.904 | ||
Not measured | 0.34 [0.20; 0.55] | < 0.001 | 0.39 [0.27; 0.55] | < 0.001 |